GleamWall
中文EN

EBS Emergent BioSolutions Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1367644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-17.7%
TTM net income YoY-443.5%
TTM EPS YoY-475.0%
Revenue 3-yr CAGR-16.2%
Net income 3-yr CAGR—

Margins

Gross margin48.4%
Operating margin-27.7%
Net margin-40.2%
FCF margin29.0%
EBITDA margin-18.4%

Returns

ROE-58.2%
ROA-21.2%
ROIC (approx.)-17.3%
Asset turnover0.53x

Leverage & solvency

Liabilities / assets68.5%
Debt / equity1.62x
Current ratio4.58x
Interest coverage-3.96x

Cash quality & payout

Operating cash flow / net income-0.77x
Accruals ratio-37.5%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$742.90M$1.04B
Cost of revenue$326.20M$681.30M
Gross profit$416.70M$362.30M
R&D expense$53.20M$70.70M
SG&A expense$186.10M$308.00M
Operating income$100.10M-$108.70M
Interest expense$59.30M$71.00M
Pretax income$82.80M-$142.90M
Income tax$30.20M$47.70M
Net income$52.60M-$190.60M
EBITDA$195.90M$100,000
EPS (basic)0.98-3.60
EPS (diluted)0.93-3.60
Weighted avg. shares (diluted)56.70M53.00M
Balance sheet
Cash & equivalents$205.40M$105.60M
Receivables$84.20M$154.50M
Inventory$343.40M$311.70M
Current assets$662.50M$598.70M
PP&E, net$205.40M$270.60M
Goodwill$0$0
Intangibles$436.50M$501.50M
Total assets$1.32B$1.39B
Current liabilities$132.20M$162.40M
Short-term debt—$0
Long-term debt$572.10M$663.70M
Total debt$572.10M$663.70M
Total liabilities$796.00M$906.90M
Shareholders' equity$522.60M$482.80M
Net debt$366.70M$558.10M
Shares outstanding52.10M54.30M
Cash flow statement
Operating cash flow$170.60M$58.70M
Capital expenditure$13.80M$22.90M
Free cash flow$156.80M$35.80M
Investing cash flow$69.40M$125.20M
Financing cash flow-$136.60M-$190.00M
Depreciation & amortization$95.80M$108.80M
Stock-based compensation$16.20M$18.00M
Share buybacks$24.90M$0

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.